Seres Therapeutics Q2 net income turns positive on VOWST sale gain
MCRB•Pipeline progress and outlook
Seres said positive topline data from the SER-155 trial in immune checkpoint inhibitor-related enterocolitis supported continued development and engagement with potential partners.
The company expects to fund operations through Q1 2027, excluding potential new partnerships or capital. Seres is evaluating its clinical development strategy for SER-155 in irEC and is seeking partners. It continues to seek funding and partners to advance the SER-155 and SER-603 programs.
Q2 results turn positive on VOWST sale gain
Seres Therapeutics said its second-quarter net income turned positive, driven by a gain from the VOWST business sale.
The company reported:
| Metric | Actual |
|---|---|
| Q2 Collaboration Revenue | $736,000 |
| Q2 EPS | $0.47 |
| Q2 Net Income | $4.58 mln |
| Q2 Operating Expenses | $22.009 mln |
| Q2 Operating Income | -$21.27 mln |
Operating expenses fell year over year due to cost reduction efforts and lease terminations. Lower research and development and general and administrative expenses reflected reduced personnel, facilities costs, and other savings initiatives. Early exit and restructuring of facility leases further reduced ongoing and future facility-related cash costs.
